STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023

Rhea-AI Summary
Gilead Sciences presents new data at IDWeek 2023, including HIV treatment outcomes and COVID-19 research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences covid-19
-
News

Gilead Board Director Kevin E. Lofton Named to List of Influential Leaders

Rhea-AI Summary
Gilead Sciences' Lead Independent Director, Kevin E. Lofton, has been recognized as one of the most influential leaders in corporate governance by the NACD Directorship 100.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
none
-
News

CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Hepatic Impairment

Rhea-AI Summary
Gilead Sciences receives positive opinion for use of Veklury in COVID-19 patients with hepatic impairment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.2%
Tags
covid-19
News

Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma

Rhea-AI Summary
Yescarta achieves a complete metabolic response of 71% at 3 months in patients with relapsed/refractory large B-cell lymphoma, exceeding expectations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
-
News

Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Rhea-AI Summary
Gilead Sciences announces promising early data from the EVOKE-02 study evaluating Trodelvy in combination with KEYTRUDA in 1L metastatic NSCLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Gilead Prices $2 Billion of Senior Unsecured Notes

Rhea-AI Summary
Gilead Sciences announces pricing of $2 billion senior unsecured notes in a public offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
News

Gilead Sciences: How One School Has Transformed Education for First-Generation Students

Rhea-AI Summary
Eastside College Preparatory School in East Palo Alto prioritizes accepting low-income and first-generation students, providing free tuition. More than 99% of students go on to college, with the Class of 2023 achieving a 100% college acceptance rate. Gilead Foundation supports the school's efforts to expand and improve.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
News

Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South

Rhea-AI Summary
Gilead Sciences celebrates the fifth anniversary of the COMPASS Initiative, a $100 million commitment to addressing the HIV epidemic in the Southern United States. The program has reached over 300,000 people and trained over 26,000 individuals in leadership development. Gilead plans to expand its support of organizations in the region. The U.S. South accounts for more than 50% of new HIV diagnoses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.7%
Tags
none
-
News

FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment

Rhea-AI Summary
FDA approves Veklury for use in COVID-19 patients with liver disease, supporting its safety profile. No dose adjustment required. Positive impact on Gilead Sciences (GILD) stock expected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
fda approval covid-19
News

Gilead Sciences to Present at Upcoming Investor Conferences

Rhea-AI Summary
Gilead Sciences executives to speak at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY